Clinical utility of nuclear imaging in the evaluation of pediatric adrenal neoplasms

Front Oncol. 2023 Jan 17:12:1081783. doi: 10.3389/fonc.2022.1081783. eCollection 2022.

Abstract

Adrenal neoplasms rarely occur in children. They can be diagnosed in the presence of endocrine, metabolic or neurological problems, an abdominal mass, more rarely an adrenal incidentaloma, or in the context of an adrenal mass discovered in the evaluation of childhood cancer including hematologic malignancy. According to standard medical practice, pediatric malignancies are almost always evaluated by 18F-fluorodeoxyglucose positron emission tomography with computed tomography ([18F]FDG PET/CT). Nuclear imaging using specific radiotracers is also an important tool for diagnosing and staging neuroblastoma, pheochromocytoma, hormone hypersecretion, or indeterminate adrenal masses. The Hippocratic oath "primum non nocere" encourages limitation of radiation in children per the ALARA concept (as low as reasonably achievable) but should not lead to the under-use of nuclear imaging because of the potential risk of inaccurate diagnosis or underestimation of the extent of disease. As in adults, nuclear imaging in children should be performed in conjunction with hormone evaluation and morphological imaging.

Keywords: PET; adrenal; cushing; neuroblastoma; nuclear imaging; pediatric neoplams; pheochromocytoma.

Publication types

  • Review

Grants and funding

This study was supported, in part, by the Intramural Research Program of the Eunice Kennedy Shriver NICHD, NIH, Bethesda, Maryland, USA, and by ALSAC. The author are especially grateful to Cherise Guess, PhD, Senior Scientific Editor, St. Jude Children’s Research Hospital, for expertise and input in reviewing the content and presentation of the manuscript.